Next date
None yet
Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The AMT consists of intratumorally delivered IUdR and local irradiation via AUTRON Therapy System.”In the company’s words, NCT04807257 on ClinicalTrials.gov
- Tested for
- Malignant Fungating Wound
- Main trialPhase 1/2
- “This is a first-in-human, single-arm, open-label, dose escalating study to determine the safety and the recommended maximum tolerated dose of the AMT in subjects with malignant cutaneous lesions. AMT is a combination therapy of a drug (IUdR) and a device (AUTRON Therapy System). IUdR is an iodinated thymidine analogue that is preferentially incorporated into DNA in rapid growing cells. The AUTRON Therapy System generates characteristic X-Ray photons around 33.4 keV, matching the K-edge energy of Iodine (33.17 keV), which can efficiently induce Auger electron emissions from IUdR in cancer…”In the company’s words, NCT04807257 on ClinicalTrials.gov
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 31 Dec 2025 | Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026